Adage Capital Partners
CAPR icon

Adage Capital Partners’s Capricor Therapeutics CAPR Stock Holding History

Adage Capital Partners’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-130,000
Closed -$3.75M – 976
2025
Q4 		$3.75M Buy
+130,000
New +$1.7M 0.01% 791

Other funds holding CAPR

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
JHC
Jones Hill Capital New York $470M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Adage Capital Partners's CAPR Position: Q1 2026 in Review

Adage Capital Partners sold out of Capricor Therapeutics (CAPR) in Q1 2026, closing a stake of 130,000 shares — an estimated $3.75M sold.

Adage Capital Partners first reported a position in CAPR in Q4 2025 and held it in 1 quarter. The position peaked at $3.75M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Adage Capital Partners reported no remaining Capricor Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Adage Capital Partners sold 130,000 Capricor Therapeutics shares in Q1 2026, an estimated $3.75M.
  • Adage Capital Partners first reported a position in Capricor Therapeutics in Q4 2025 and held it in 1 quarter.
  • Adage Capital Partners's Capricor Therapeutics position peaked at $3.75M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.